CDKN2A and melanoma: While early stage (I-IIA) melanoma has 5-year overall survival rates of greater than 90%, it worsens in more advanced disease [1, 2] Melanoma arises in melanocytes due to a combination of genetic predisposition (CDKN2A, CDK4) and acquired mutations (BRAF, MEK) from ultraviolet light-induced damage.